Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.

Abstract

(+)-Cyanidanol-3 is considered to have cytoprotective effect in toxic liver injury. A randomized clinical trial was carried out in alcoholic precirrhotic patients and in chronic active hepatitis with (+)-cyanidanol-3 versus placebo. The daily dose of the drug was 1.5-2.0 g for a one-year period. A: Toxic alcoholic precirrhotic liver disease: 38 patients were treated with (+)-cyanidanol-3, 36 with placebo. We found significant improvement in the subjective symptome like asthenia and anorexia, and in serum aspartate-transaminase (GOT) levels. However, it is possible that the improvement was in part due to abstinence from alcohol. B: Chronic active hepatitis: previously introduced continuous prednisolone therapy (10-15 mg/day) was combined with (+)-cyanidanol-3 in 13 patients and with placebo in 12 controls. The results showed a more favourable, but not significantly better response in patients receiving (+)-cyanidanol-3 versus placebo. We concluded that the drug might be of benefit in some cases with chronic active hepatitis as an adjunct to corticoid therapy.

• Authors: M Abonyi, S Kisfaludy, F Szalay
• Journal: Acta physiologica Hungarica (Acta Physiol Hung) Vol. 64 Issue 3-4 Pg. 455-60 ( 1984) ISSN: 0231-424X [Print] Hungary
• PMID: 6397971 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzopyrans
• Catechin
• Prednisolone

Topics

• Adult
• Aged
• Benzopyrans (therapeutic use)
• Catechin (therapeutic use)
• Clinical Trials as Topic
• Drug Therapy, Combination
• Hepatitis, Alcoholic (drug therapy)
• Hepatitis, Chronic (drug therapy)
• Humans
• Liver (drug effects)
• Liver Function Tests
• Middle Aged
• Prednisolone (therapeutic use)